Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China.
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, Yu H, Dong F, Liao A, Ma Y, Liu Q, Liu S, Jing H, Fu R, Ma LM, Liu H, Sun W, Bao L, Wu Y, Chen W, Zhuang J.
Zhuang Z, et al. Among authors: liu h, liu s, liu q.
Front Oncol. 2023 Apr 20;13:1028571. doi: 10.3389/fonc.2023.1028571. eCollection 2023.
Front Oncol. 2023.
PMID: 37152063
Free PMC article.